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Abstract
BACKGROUND—Patients are frequently discharged with central venous catheters (CVCs) for 
home infusion therapy.
OBJECTIVE—To study a prospective cohort of patients receiving home infusion therapy to 
identify environmental and other risk factors for complications.
DESIGN—Prospective cohort study between March and December 2015.
SETTING—Home infusion therapy after discharge from academic medical centers.
PARTICIPANTS—Of 368 eligible patients discharged from 2 academic hospitals to home with 
peripherally inserted central catheters and tunneled CVCs, 222 consented. Patients remained in the 
study until 30 days after CVC removal.
METHODS—Patients underwent chart abstraction and monthly telephone surveys while the CVC 
was in place, focusing on complications and environmental exposures. Multivariable analyses 
estimated adjusted odds ratios and adjusted incident rate ratios between clinical, demographic, and 
environmental risk factors and 30-day readmissions or CVC complications.
RESULTS—Of 222 patients, total parenteral nutrition was associated with increased 30-day 
readmissions (adjusted odds ratio, 4.80 [95% CI, 1.51–15.21) and CVC complications (adjusted 
odds ratio, 2.41 [95% CI, 1.09–5.33]). Exposure to soil through gardening or yard work was 
associated with a decreased likelihood of readmissions (adjusted odds ratio, 0.09 [95% CI, 0.01–
0.74]). Other environmental exposures were not associated with CVC complications.
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CONCLUSIONS—complications and readmissions were common and associated with the use of 
total parenteral nutrition. Common environmental exposures (well water, cooking with raw meat, 
or pets) did not increase the rate of CVC complications, whereas soil exposures were associated 
with decreased readmissions. Interventions to decrease home CVC complications should focus on 
total parenteral nutrition patients.
Complications of central venous catheters (CVCs) such as central line–associated 
bloodstream infections (CLABSI) have been increasingly recognized over the past 3 decades 
and are reportable as a quality indicator in inpatient settings.1 However, patients needing 
long-term CVCs for chemotherapy, total parenteral nutrition (TPN), parenteral 
antimicrobials, and other indications often maintain CVCs at home, with support from home 
nursing and home infusion agencies.2 The advantages of maintaining CVCs in the home are 
clear: patients can remain in their usual environments and maintain their independence. 
More than 1.2 million courses of home infusion therapy are delivered in the United States 
yearly.3 Despite this, complications associated with CVCs in the home have not been a focus 
of research or regulation.
Patients with home CVCs are at risk for CLABSI as well as catheter-associated venous 
thromboembolism (CA-VTE), phlebitis, and occlusion. Criteria for defining home 
healthcare-associated infections have been published,4 but their implementation varies 
among home infusion agencies.5 Reported rates of home CLABSI range from 0 to 36 
CLABSI per 1,000 CVC-days.6–23 CA-VTEs are another increasingly recognized 
complication of CVCs,22,24 but rates of home CA-VTEs have not been well described. Risk 
factors for CVC complications occurring at home have also not been well characterized. In 
particular, the role of environmental risk factors unique to the home setting, such as 
exposures to well water, uncooked meats, pets, or soil, has not been explored.
We describe outcomes in a prospective cohort of patients with CVCs discharged from the 




In this prospective cohort, eligible patients were at least 18 years of age and discharged 
between March and December 2015 with peripherally inserted central catheters (PICCs) or 
tunneled CVCs. Patients were ineligible if they were in hospice care, did not speak English, 
or were unable to verbally consent. Eligible patients were contacted via telephone to consent 
for the study 2 weeks after hospital discharge, to allow patients time to settle into a routine 
after hospital discharge. Three attempts were made to contact each patient during business 
hours.
Setting
We included patients requiring home infusion therapy who were discharged from 2 large 
tertiary-care academic medical centers affiliated with 1 urban American medical school 
(Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center, Baltimore, 
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Maryland). Home infusion agencies provided medication and supplies, and home nursing 
agencies provided training and support in CVC care. Patients could have used any home 
infusion or home nursing agency.
Instrument
Consenting patients underwent an initial 20-minute telephone survey focusing on 
environmental exposures, readmissions and emergency department visits, and CVC 
complications. Surveys were repeated monthly while the CVC was in place (Supplemental 
Table 1). The survey instrument was piloted among 10 patients before the study, with 
changes made on the basis of their feedback.
Medical charts were abstracted for demographic information, CVC characteristics, CVC 
indication, clinical data, readmissions, emergency department visits, and CVC complications 
through 1 month after CVC removal. Interrater reliability for 2 reviewers (S.C.K. and D.W.) 
was calculated on the basis of CVC complications and readmissions on a subset of 20 
patients. On cases reviewed independently where concerns over ascertainment of variable 
categorization was raised by either reviewer, the reviewers conferred to reach consensus.
Variables
Because few enrolled patients were Asian American, Hispanic, or other racial/ethnic groups, 
racial/ethnic group was categorized as white, black, or other race. Insurer was characterized 
as Medicare, Medicaid, private, or self-pay/uninsured. Distance from discharging hospital 
was calculated from the center of the patient’s home zip code. Patients could have more than 
1 indication for CVC. The Charlson comorbidity index (CCI)25 was calculated and 
dichotomized at 2 on the basis of its distribution with the outcome. CVC-days were 
calculated as the number of days between hospital discharge and CVC removal.
Environmental exposures (persons doing CVC care, and exposure to well water, pets, soil, or 
uncooked meats) were considered present if patients had acknowledged these exposures 
during any of the telephone surveys. Patients could have listed more than 1 person assisting 
with CVC care. Water source was categorized as well or reservoir/municipal source. 
Exposure to pets was definedd as a pet in the home. Exposure to soil was definedd as 
gardening or outdoor yard work. Exposure to raw meats was definedd as handling uncooked 
poultry, pork, beef, seafood, or other meats.
Outcomes were based on patient self-report and medical chart review. The primary outcome 
was any CVC complication. CVC complication was having any of the following: CLABSI, 
CA-VTE, bloodstream infection, tunnel infection, or CVC occlusion, dislodgement, 
accidental removal, kinking, coiling, breaking, phlebitis, or linking. CA-VTE was definedd 
as a venous thromboembolism on imaging in any location, because PICCs may be risk 
factors for upper and lower venous thromboembolisms.22 CLABSI were definedd on the 
basis of Association for Professionals in Infection Control criteria for CLABSI in home 
infusion4 (adapted from National Healthcare Safety Network CLABSI definitions26). 
Bloodstream infection was at least 2 positive cultures of blood samples within 48 hours of 
CVC removal that did not meet CLABSI criteria.26 CVC occlusion was definedd as a 
blockage in at least 1 CVC lumen necessitating the medication alteplase to clear the 
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occlusion. CVC complications were measured per 1,000 home CVC-days. The secondary 
outcome was all-cause admissions within 30 days of hospital discharge. We additionally 
reported all-cause readmissions throughout the study—that is, within 30 days of CVC 
removal.
Data Analysis
Descriptive statistics were used for demographic, clinical, CVC, environmental exposure, 
and outcome data; the software was Stata, version 14.0 (StataCorp). Predictors included 
demographic and clinical variables and environmental exposures. Univariate and 
multivariate Poisson regression was used to estimate predictors of overall CVC 
complications. Univariate and multivariate logistic regression was used to determine 
predictors of all-cause 30-day readmissions. Covariates were considered if the association 
with the outcome of interest had P ≤ .20 (2-sided), and were added in a stepwise fashion if 
the covariate led to at least 10% change in the point estimate. Soil exposure was removed 
from the CVC complication model because no patients with soil exposure had CVC 
complications. P <.05 was considered statistically significant. A total of 220 patients were 
needed to achieve 80% power to calculate a 50% difference in the primary relationship.
Basic demographic and CVC information as well as 30-day all-cause readmissions were 
abstracted for the 147 patients who were eligible for the study but either declined 
participation or were unable to be reached (Supplemental Table 2).
The study was approved as expedited with oral consent by the Johns Hopkins University 
School of Medicine Institutional Review Board.
RESULTS
Of 368 eligible patients, 222 (60.3%) enrolled in the study (Figure 1), providing 11,928 
CVC-days of data. Most patients were white (160 [72.1%]) and privately insured (151 
[68.0%]) (Table 1). Most patients received outpatient parenteral antimicrobial therapy (163 
[73.4%]) and had PICCs (145 [65.3%]). Patients maintained CVCs for a mean of 53.6 days 
after discharge. A minority experienced exposure to soil (17 [7.7%]) (Table 2).
As shown in Table 3, 52 patients (23.4%) had a CVC complication (4.37/1,000 CVC-days). 
CA-VTE occurred at a rate of 0.84/1,000 CVC-days, and CLABSI occurred at a rate of 
1.18/1,000 CVC-days. More than one-quarter of patients (60 [27.0%]) were readmitted 
within 30 days of hospital discharge. Of readmitted patients, 8 (13.3%) had planned 
readmissions, 14 (23.3%) had readmissions related to a CVC complication, and 10 (16.7%) 
were outpatient parenteral antimicrobial therapy patients with worsening infections.
We found that having Medicaid as a payer (versus having private insurers as payers) was 
associated with CVC complications on unadjusted analyses (incidence rate ratio, 2.44 [95% 
CI, 1.09–5.47]), but was no longer significant once we adjusted for covariates (Table 4). 
TPN was associated with an increased rate of CVC complications (incidence rate ratio, 1.96 
[95% CI, 1.09–3.53]; adjusted incidence rate ratio, 2.41 [95% CI, 1.09–5.33]). No 
environmental exposures were associated with CVC complications.
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TPN was also associated with an increased likelihood of 30-day readmissions (odds ratio 
[OR], 3.04 [95% CI, 1.39–6.60]; adjusted OR, 4.80 [95% CI, 1.51–15.21]). Living a 
moderate distance from the discharging hospital (>50 but <75 km) was associated with an 
increased likelihood of readmissions compared with living near the hospital (<25 km) in 
unadjusted analyses (OR, 2.54 [95% CI, 1.07–6.00]), but this was no longer statistically 
significant once adjusted for covariates. Tunneled CVCs (vs PICCs) were associated with an 
increased likelihood of 30-day readmissions (OR, 2.22 [95% CI, 1.21–4.08]), but this was 
also no longer statistically significant once adjusted for covariates. CCI at least 2 was also 
associated with an increased likelihood of 30-day readmissions (OR, 2.90 [95% CI, 1.28–
6.56]), but this was no longer statistically significant once adjusted for covariates. Of the 
environmental exposures, person doing the infusion, pets, well water, and cooking with raw 
meats were not associated with readmissions. However, soil exposure (through gardening or 
yard work) was associated with a decreased likelihood of readmission (OR, 0.15 [95% CI, 
0.03–0.69]; adjusted OR, 0.09 [95% CI, 0.01–0.74]).
We examined whether there were differences in characteristics between eligible patients who 
did and did not participate in the study, and found none (Supplemental Table 2).
We calculated differences between the 2 raters on the clinical outcomes. Agreement was 
very good on all measures: readmissions (κ =0.80), CA-VTE (κ =1.00), CLABSI (κ =1.00), 
and bloodstream infection (κ =1.00).
DISCUSSION
Complications among patients with home CVCs are common yet underappreciated, and the 
risks associated with these are not well described. Understanding relationships between 
environmental exposures and CVC complications is key to counseling patients, as a survey 
of pediatric home TPN providers showed inconsistency even in advising children with CVCs 
to avoid swimming.27 In our prospective cohort of patients on home infusion therapy, almost 
one-quarter had a complication from their catheter. Similarly, more than one-quarter of these 
patients were readmitted within 30 days of discharge. Our study reinforces the burden of 
CVC complications and readmissions among home infusion therapy patients.
As in other studies, TPN was associated with both CVC complications and 30-day 
readmissions.6 Patients on TPN may be more likely to have CLABSI owing to poor venous 
access that necessitates attempts at catheter salvage and owing to the infusate creating a 
favorable microorganism environment.6 Preparing TPN requires multiple manipulations to 
the infusate by patients and caregivers. The complexity of the tasks required in preparing 
TPN may further predispose patients to CLABSI. Also, TPN components may lead to 
increased CVC occlusions. Many readmissions in TPN patients may be due to CVC 
complications. However, patients needing TPN may also have more severe illnesses. 
Although the CCI counts and weights comorbidities, it is not a measure of illness severity, so 
we did not fully control for severity of illness.
Interestingly, having Medicaid (but not Medicare) as a payer was associated with CVC 
complications on unadjusted analyses. Perhaps Medicaid patients are more likely to have 
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comorbidities or other risk factors (such as smoking) that increase the risk of CVC 
complications. Also, age was not associated with an increased rate of CVC complications or 
likelihood of readmissions, as in other studies showing that age was not associated with 
CLABSI,28,29 CVC occlusion,28 other line events,29 or readmissions.30–33
Additional risk factors for readmissions were noted on univariate analyses but were no 
longer significant when we adjusted for confounders. Tunneled CVCs, higher CCI scores, 
and living more than 50 but less than 75 km from the hospital were each associated with 
fewer 30-day readmissions, but these relationships were no longer significant after 
adjustment. Patients with tunneled CVC are more likely to be on treatments like TPN or 
chemotherapy, so controlling for receipt of TPN or chemotherapy may make the association 
between tunneled CVC and readmissions nonsignificant. Similarly, CCI scores are partially 
driven by malignant tumor,25 so adjustment for chemotherapy may make relationships 
between CCI and readmissions nonsignificant. Because the discharging hospitals are tertiary 
referral centers, patients living further away may be sicker than local patients using the 
hospitals for routine conditions, and controlling for comorbidities may make the relationship 
between distance and readmissions nonsignificant.
Our primary goal was to examine whether home environmental factors increased the CVC 
complication rate. No environmental exposures investigated were associated with CVC 
complications. Interestingly, soil exposure was associated with a decreased likelihood of 
readmissions. Although this was surprising, as we had hypothesized that patients exposed to 
soil would have a higher rate of CVC complications, potentially leading to readmissions, it 
is possible that patients who are able to garden or perform yard work are healthier than other 
patients in the cohort. In addition, this study is likely under-powered to understand the role 
of environmental exposures in CVC complications.
Readmissions were frequent. Our population had a 27.0% 30-day readmission rate, higher 
than the 16% 30-day readmission rate among Medicare patients in the state where the study 
took place and in the 2 hospitals involved in the study.34 To reduce readmissions in this 
population requires close management of other comorbidities, reduction of CVC 
complications, and aggressive management of underlying infections among patients 
receiving outpatient parenteral antimicrobial therapy.
This study had several limitations. First, our study involved a small number of patients and 
we enrolled only 3 in 5 eligible patients. Fortunately, those patients who participated and 
those who did not had similar basic demographic and clinical features and 30-day 
readmissions, suggesting that there was not participation bias. Second, this study focused on 
patients discharged from 2 academic medical centers in 1 major American city, so results 
may not be generalizable to other regions and may represent a best-case scenario. Third, 
processes of care and outcomes in other settings where outpatient infusion therapy is 
delivered (such as outpatient infusion centers) may be different than in our population. We 
focused on this group because complications experienced in primarily self-administered 
home infusion therapy are important to highlight and likely different from complications 
experienced in an outpatient infusion center, where a patient may be at home with a CVC 
but where a trained medical professional in a clinic performs tasks associated with the 
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infusion or the CVC. Fourth, because most of our patient population receives home infusion 
therapy after hospital discharge, we focused on this population. Our results may not reflect 
those starting home infusion therapy as outpatients. Fifth, our results may not apply to 
patients receiving infusion therapy via midlines, medi-ports, or other types of access. We 
focused on PICCs and tunneled CVCs because the processes of maintaining these catheters 
were similar.
Our study included a telephone survey in which we asked patients about complications and 
environmental risks. This allowed us to capture a more complete picture of complications 
and exposures—that is, a more complete picture of patient experiences—than we would 
have with medical chart review alone. For example, patients received services from many 
home infusion agencies, most of which were not integrated into the shared medical records 
system of the hospitals studied. If a complication was documented by the home infusion 
agency but not by a provider affiliated with the hospitals, the complication would have been 
undercounted.
We have described outcomes among patients receiving home infusion therapy. Nationally, 
we know relatively little about home infusion patients because typical database sources 
(such as Medicare) used to study other conditions may be incomplete for studies of home 
infusion therapy: Medicare does not cover many home infusion services.35 Medicare status 
and increased age were not associated with CVC complications or 30-day readmissions in 
this study. Given that alternatives to home infusion therapy may include skilled nursing 
home stays, extended acute inpatient hospital stays, suboptimal oral therapies, or daily visits 
to infusion centers, we can reassess whether Medicare should cover home infusion therapies 
to the same level as private insurers.35 Patients on Medicare who do not have secondary 
insurances may not be covered for all infusion-related services and equipment needed.35 
Congressional bills to remedy this disparity in services are currently pending in 
committee.36,37
The current study also supports the need to better benchmark CVC complications among 
home infusion patients; using rigorous criteria in defining CVC outcomes (as in this study) 
demonstrates that CVC complications may occur at a rate of 4.37/1,000 home CVC-days. A 
2011 survey of home infusion pharmacies serving pediatric oncology patients showed that 
none used all elements of the National Healthcare Safety Network/Association for 
Professionals in Infection Control CLABSI definition and adjudication process.5 A national 
registry of home infusion patients would allow for better benchmarking of outcomes.
Home infusion therapy provides a safe way for patients to receive therapies in the home and 
is increasingly used to avoid hospitalizations and control costs. Traditional risk factors may 
play a larger role in complications than environmental risk factors. More studies in home 
infusion therapy are needed to understand the frequency of complications and how to reduce 
them, particularly in high-risk subpopulations such as TPN patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Flow chart for inclusion of participants in study of environmental exposures and the risk of 
central venous catheter complications and readmissions in home infusion therapy patients.
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TABLE 1
Demographic and Clinical Characteristics of 222 Patients Discharged From 2 Academic Medical Centers to 
Home With Tunneled CVCs and PICCs
Characteristic Value
Female sex 111 (50.0%)
Race/ethnicity
 White 160 (72.1%)
 Black 47 (21.2%)
 Other 15 (6.8%)
Age at discharge, mean (SD), y 52.7 (14.6)
Insurance
 Private 151 (68.0%)
 Medicaid 21 (9.5%)
 Medicare 48 (21.6%)
 Uninsured or self-pay 2 (0.9%)
Distance from discharging hospital
 <25 km (<15.5 miles) 106 (47.8%)
 25 km to <50 km (15.5 to <31.1 miles) 46 (20.7%)
 50 km to <75 km (31.1 to <46.6 miles) 28 (12.6%)
 75 km to <100 km (46.6 to <62.1 miles) 15 (6.8%)
 ≥100 km (≥62.1 miles) 27 (12.2%)
Indication for CVCa
 Outpatient parenteral antimicrobial therapy 163 (73.4%)
 Chemotherapy 48 (21.6%)
 Total parenteral nutrition 31 (14.0%)
 Other indication 17 (7.7%)
Type of CVC
 PICC 145 (65.3%)
 Tunneled CVC 77 (34.7%)
CVC lumens
 1 74 (33.3%)
 2 148 (66.7%)
Days with CVC after hospital discharge, mean (SD) 53.6 (50.8)
Comorbidity
 Diabetes mellitus 63 (28.4%)
 Chronic renal disease 56 (25.2%)
 Malignant tumor (treated in past 6 months) 91 (41.0%)
 Prior venous thromboembolism 27 (12.2%)
Charlson comorbidity index, mean (SD) 5.14 (3.29)
NOTE. Data are no. (%) of patients unless otherwise indicated. CVC, central venous catheter; PICC, peripherally inserted central catheter.
a
Patients could have more than 1 indication for CVC; for example, a patient requiring both total parenteral nutrition and outpatient parenteral 
antimicrobial therapy would be indicated as having both indications. However, to be noted as having a CVC indication for only venous access for 
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blood draws or for as-needed infusions, this had to be the sole indication for CVC. Other indications included access for intermittent infusions (n 
=9) and access for phlebotomy (n =8).
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TABLE 2
Environmental and Behavioral Risk Factors Among 222 Patients Discharged From 2 Academic Medical 
Centers to Home With Tunneled CVCs and PICCs
Characteristic No. (%) of patients
Person performing infusiona
 Self 151 (68.0%)
 Friend/family member 98 (44.1%)
 Nurse 19 (8.6%)
Presence of pets in the home
 Any pet 122 (55.0%)
 Dog 86 (38.7%)
 Cat 50 (22.5%)
 Other mammal (rabbit =2, ferret =1, sugar glider =1) 4 (1.8%)
 Fish 6 (2.7%)
 Bird 2 (0.9%)
 Reptile (turtle =2, lizard =1, snake =1) 4 (1.8%)
Soil exposure via gardening or yard work with CVC in place 17 (7.7%)
Water source: well (unknown =16) 39/206 (18.9%)
Cooking with raw meat with CVC in place 73 (32.9%)
NOTE. CVC, central venous catheter; PICC, peripherally inserted central catheter.
a
Study participants could name more than 1 person performing infusions; for example, if the patient performs infusions during the day, and a 
significant other performs infusions in the evening; or if a nurse performs infusions on some days and the patient performs infusions on other days.
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TABLE 3
Prevalence and Rates of Outcomes Among 222 Patients Discharged to Home From 2 Academic Medical 
Centers With Tunneled CVCs and PICCs
Outcome No. (%) of patients
Rate per 1,000 home CVC-days (95% 
CI)
Readmission at any time during study 97 (43.7%) N/A
 Readmission within 30 days of hospital discharge 60 (27.0%) N/A
 Readmission related to CVC complication (of 60 30-day readmissions) 14/60 (23.3%) N/A
 Unplanned readmissions (of 60 30-day readmissions) 52/60 (86.7%) N/A
ED visit at any time during study 69 (31.1%) N/A
 ED visit within 30 days of hospital discharge 43 (19.4%) N/A
 ED visit within 30 days for CVC complication (of 43 visits) 12/43 (27.9%) N/A
Catheter occlusion resulting in alteplase 21 (9.5%) 1.77 (1.15–2.71)
CVC inadvertently removed or fell out 3 (1.4%) 0.25 (0.08–0.78)
Catheter-associated venous thromboembolism 10 (4.5%) 0.84 (0.45–1.56)
CLABSI 14 (6.3%) 1.18 (0.70–1.99)
BSI not meeting CLABSI criteria 8 (3.6%) 0.67 (0.34–1.35)
Any CVC complication 52 (23.4%) 4.37 (3.33–5.74)
NOTE. There were 11,928 total central venous catheter (CVC)–days (days between hospital discharge and removal of CVC). BSI, bloodstream 
infection; CLABSI, central line–associated bloodstream infection; ED, emergency department; PICC, peripherally inserted central catheter.
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TABLE 4
Univariable and Multivariable Associations of Characteristics With Readmissions and Total CVC 
Complications Among 222 Patients Discharged With Tunneled CVCs and PICCs
Variable
Any CVC complication (N =52) Readmission within 30 Days (N =60)
IRR (95% CI) Adjusted IRR (95% CI) OR (95% CI) Adjusted OR (95% CI)
Female sex (vs male) 1.05 (0.61–1.81) N/A 1.10 (0.76–2.20) Not included
Race/ethnicity
 White – – – Not included
 Black 1.52 (0.81–2.87) N/A 0.85 (0.41–1.78) Not included
 Other 0.74 (0.18–3.06) N/A 0.38 (0.08–1.76) Not included
Age ≥50 y 0.60 (0.34–1.05) 0.73 (0.37–1.41) 1.30 (0.69–2.45) 1.38 (0.62–3.05)
Insurancea
 Private – – – –
 Medicaid 2.44 (1.09–5.47) 1.66 (0.64–4.31) 0.48 (0.13–1.71) 0.49 (0.12–2.06)
 Medicare 0.60 (0.28–1.29) 0.64 (0.27–1.52) 1.57 (0.79–3.15) 1.40 (0.60–3.29)
Distance from discharging hospital
<25 km (referent) – N/A – –
 25 to <50 km 1.18 (0.59–2.37) N/A 1.03 (0.47–2.28) 1.11 (0.43–2.89)
 50 to <75 km 1.14 (0.49–2.66) N/A 2.54 (1.07–6.00) 2.28 (0.83–6.27)
 75 to <100 km 1.01 (0.35–2.91) N/A Not included Not included
 ≥100 km 0.68 (0.28–1.66) N/A 1.23 (0.48–3.14) 0.96 (0.30–3.03)
Tunneled CVC vs PICC 0.78 (0.45–1.35) 0.88 (0.43–1.80) 2.22 (1.21–4.08) 1.53 (0.66–3.53)
Indication for CVC
 OPAT 1.37 (0.75–2.49) 1.42 (0.68–2.97) 0.57 (0.30–1.08) 1.53 (0.58–4.04)
 Chemotherapy 0.58 (0.30–1.13) 0.77 (0.29–2.05) 1.48 (0.74–2.95) 1.59 (0.55–4.67)
 TPN 1.96 (1.09–3.53) 2.41 (1.09–5.33) 3.04 (1.39–6.60) 4.80 (1.51–15.21)
Charlson comorbidity index ≥2 0.77 (0.41–1.47) 1.07 (0.51–2.26) 2.90 (1.28–6.56) 2.23 (0.85–5.88)
Diagnosed with or treated for malignant tumor 
within 6 mo.
0.77 (0.45–1.33) Not included 1.38 (0.76–2.50) Not included
Chronic renal disease (≥stage III) 0.61 (0.32–1.16) Not included 1.75 (0.92–3.36) Not included
Person performing infusion
 Patient 1.58 (0.79–3.15) Not included 0.93 (0.50–1.75) Not included
 Friend or family 1.56 (0.83–2.92) Not included 1.40 (0.74–2.63) Not included
 Nurse 0.98 (0.55–1.73) Not included 0.70 (0.22–2.20) Not included
Pets in the home 0.85 (0.39–1.81) 1.37 (0.72–2.61) 0.91 (0.50–1.66) 1.74 (0.83–3.69)
Well water (vs municipal or reservoir water) 1.11 (0.64–1.91) 0.77 (0.34–1.75) 1.10 (0.50–2.39) 0.59 (0.20–1.71)
Soil exposure from gardening or yard work 0.89 (0.43–1.84) 0.00 (Not included) 0.15 (0.03–0.69) 0.09 (0.01–0.74)
Handling of raw meats 1.22 (0.70–2.12) 1.52 (0.82–1.75) 0.60 (0.31–1.16) 0.62 (0.28–1.41)
NOTE. CVC, central venous catheter; IRR, incidence rate ratio; OPAT, outpatient parenteral antimicrobial therapy; OR, odds ratio; PICC, 
peripherally inserted central catheter; TPN, total parenteral nutrition.
a
Two uninsured patients are missing.
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